Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy?

Figures & data

Table I.  Comparison of preoperative prognostic markers in PSA-recurrence and no-recurrence group, Number of patients*, [Median], (range)

	Total	Non-recurrence	Recurrence
PSA ng/ml	9.7[8]	5.48(2-9.7)	13.4(3.6-28.7)
Gleason score 6	32*	21*	11*
Gleason score 7	18*	4*	14*
T1	23*	18*	7
T2	27*	7*	18*
Core cancer length, mm	10.4[8]	8.1[7]	11.9[8.9]
TVC	5.00(2.75-13.40)	4.39(2.75-6.80)	5.52(3.10-13.40)

Table II.  The result of univariate analysis. The odds ratio for PSA recurrence is calculated for each preoperative prognostic marker.

Prognostic marker	Odds ratio	p-value
PSA	1.69 [1.36-2.12]	<0.0001
Gleason score biopsy	1.05 [1.02-1.10]	0.0075
T-stege	6.53 [2.72-15.66]	<0.0001
TVC biopsy	1.97 [1.11-3.48]	0.02

Figure 1. Kaplan-meier analysis of time to PSA-relapse in relation with different quartiles of TVC in core biopsy. Patients with highest TVC are in first quartile. The PSA-free survival rate were 17% in First quartile▪, 46% in second quartile□, 54% in Third quartile▵ and 67% in Forth quartile• (P = 0.020)

Figure 2. The relationship between MVD in preoperative core biopsy and postoperative prostate specimen. Correlation coefficient of 0.41 was found (P = 0.003)

Figure 3. a. Area of prostate cancer with clearly identifiable microvessels (400x). b. Detail of another viewfield showing many small microvessels (1000x). Bar denote 10 micrometer. Immunostaining with anti CD34.